Legend Biotech Corp Total Liabilities
Legend Biotech Corp total liabilities. Based on the latest financial reports, Legend Biotech Corp (LEGN) has total liabilities worth $521.32 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Legend Biotech Corp liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Legend Biotech Corp (2017–2025)
Total liabilities of Legend Biotech Corp from 2017 to 2025. This chart illustrates how Legend Biotech Corp's total liabilities have evolved over time, based on quarterly financial data. Explore investment intensity of Legend Biotech Corp to see how much of total assets are deployed in long-term investments.
Legend Biotech Corp Competitors by Total Liabilities
The table below lists competitors of Legend Biotech Corp ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Turkcell Iletisim Hizmetleri AS
NYSE:TKC
|
USA | $248.39 Billion |
|
AP Memory Technology Corp
TW:6531
|
Taiwan | NT$3.56 Billion |
|
Ningbo Joyson Electronic Corp
SHG:600699
|
China | CN¥45.99 Billion |
|
Shenzhen MTC Co Ltd
SHE:002429
|
China | CN¥11.05 Billion |
|
Faw Car Co Ltd
SHE:000800
|
China | CN¥55.50 Billion |
|
Xinfengming Group Co Ltd
SHG:603225
|
China | CN¥46.00 Billion |
|
Shanghai Wanye Enterprises Co Ltd
SHG:600641
|
China | CN¥4.10 Billion |
|
Vontobel Holding
SW:VONN
|
Switzerland | CHF32.26 Billion |
Liability Composition Analysis (2017–2025)
This chart breaks down Legend Biotech Corp's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see LEGN asset base.
Liquidity & Leverage Metrics
Legend Biotech Corp Total Liabilities Ratios Explained
Legend Biotech Corp total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.04 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.42 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.30 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Legend Biotech Corp's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Legend Biotech Corp (2017–2025)
The table below shows the annual total liabilities of Legend Biotech Corp from 2017 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $731.60 Million | +16.20% |
| 2024-12-31 | $629.61 Million | +5.42% |
| 2023-12-31 | $597.24 Million | +1.80% |
| 2022-12-31 | $586.65 Million | +65.95% |
| 2021-12-31 | $353.52 Million | +189.13% |
| 2020-12-31 | $122.27 Million | -70.22% |
| 2019-12-31 | $410.58 Million | -2.33% |
| 2018-12-31 | $420.40 Million | +85.59% |
| 2017-12-31 | $226.53 Million | -- |
About Legend Biotech Corp
Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of mult… Read more